(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The Response to Fake General Knowledge: Investigating the Eventual fate of artificial intelligence - 2Strengthening through Wellness: Individual Preparation Achievement
- 3Vote In favor of Your Favored Distributed computing Administration
- 4Investigating the World's Chief Authentic Urban communities to Visit
- 5How to watch the ‘Wicked: One Wonderful Night’ special — now streaming
- Shredded cheese sold in dozens of states recalled due to potential for metal fragment contamination
- Geomagnetic storm grounds launch of Mars space weather satellites
- Savvy Tips for Seniors Hyundai IONIQ EV
- Public Parks in the USA
- The Job of a Land Legal counselor in Property Exchanges
- CDC's upcoming vote on hepatitis B vaccine could impact childhood immunization
- Vote In favor of Your Favored Keeping an eye on
- Find the Techniques for Powerful Review Propensities: Opening Your Scholarly Potential
- UN panel says Israel operating 'de facto policy of torture'
